{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:42:38Z","timestamp":1785825758801,"version":"3.56.0"},"reference-count":164,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clbc.2025.12.001","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:33:12Z","timestamp":1765413192000},"page":"17-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ADAM and ADAMTS Proteases in Breast Cancer: Molecular Mechanisms and Therapeutic Implications"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0381-9160","authenticated-orcid":false,"given":"Chanchal","family":"Badhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju Rawat","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shradha Devi","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deependra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2025.12.001_bib0001","article-title":"Breast cancer statistics 2024","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0002","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 & projection for 2025: result from national cancer registry programme, India","volume":"156","author":"Sathishkumar","year":"2022","journal-title":"Indian J Med Res"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102569","article-title":"Breast cancer\u2014epidemiology, classification, pathogenesis and treatment (review of literature)","volume":"14","author":"Smolarz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.clbc.2025.12.001_bib0004","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3126\/ajms.v13i7.44536","article-title":"The study of correlation of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer and its incidence in a tertiary center hospital in south India","volume":"13","author":"Shashikumar","year":"2022","journal-title":"Asian J Med Sci"},{"issue":"17","key":"10.1016\/j.clbc.2025.12.001_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"Spec Iss 4","key":"10.1016\/j.clbc.2025.12.001_bib0006","first-page":"6","article-title":"Breast cancer and associated factors: a review","volume":"8","author":"Ataollahi","year":"2015","journal-title":"J Med Life"},{"issue":"8","key":"10.1016\/j.clbc.2025.12.001_bib0007","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/15384047.2016.1177684","article-title":"The ADAMs family of proteases as targets for the treatment of cancer","volume":"17","author":"Mullooly","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0008","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/cancers17101703","article-title":"ADAM proteases in cancer: biological roles, therapeutic challenges, and emerging opportunities","volume":"17","author":"Arora","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1559-0275-8-9","article-title":"The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?","volume":"8","author":"Duffy","year":"2011","journal-title":"Clin Proteomics"},{"issue":"12","key":"10.1016\/j.clbc.2025.12.001_bib0010","doi-asserted-by":"crossref","first-page":"15359","DOI":"10.1007\/s13277-016-5418-y","article-title":"The role of ADAM17 in tumorigenesis and progression of breast cancer","volume":"37","author":"Shen","year":"2016","journal-title":"Tumor Biol"},{"issue":"24_Supplement","key":"10.1016\/j.clbc.2025.12.001_bib0011","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1158\/0008-5472.SABCS-09-5056","article-title":"Clinical benefit of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17, in combination with trastuzumab in metastatic HER2 positive breast cancer patients","volume":"69","author":"Friedman","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2025.12.001_bib0012","doi-asserted-by":"crossref","unstructured":"Xu J, Yang X, Shu P, Wang W, Wu H, Wang Z. Regulation of tmTNF-\u03b1 processing by FRMD8 in triple-negative breast cancer metastasis: insights into molecular pathway dynamics. 2024. doi:10.1101\/2024.09.26.615107.","DOI":"10.1101\/2024.09.26.615107"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0013","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ajpath.2013.08.002","article-title":"Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine","volume":"183","author":"Rivenbark","year":"2013","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0014","article-title":"Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy","volume":"15","author":"Luo","year":"2024","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.clbc.2025.12.001_bib0015","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1073\/pnas.1505649112","article-title":"iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling","volume":"112","author":"Li","year":"2015","journal-title":"Proc Natl Acad Sci u S a"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0016","first-page":"41","article-title":"Association of iRhom1 and iRhom2 expression with prognosis in patients with cervical cancer and possible signaling pathways","volume":"43","author":"Xu","year":"2020","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0017","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41416-021-01328-7","article-title":"Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression","volume":"125","author":"L\u00fc\u00f6nd","year":"2021","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044002","article-title":"Crosstalk of inflammatory cytokines within the breast tumor microenvironment","volume":"24","author":"Habanjar","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1007\/s13402-019-00489-1","article-title":"The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches","volume":"43","author":"Cruceriu","year":"2020","journal-title":"Cell Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","article-title":"Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance","volume":"43","author":"Bhat","year":"2024","journal-title":"Cancer Metastasis Rev"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0021","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.7150\/ijbs.92988","article-title":"The burgeoning significance of liquid-liquid phase separation in the pathogenesis and therapeutics of cancers","volume":"20","author":"Xu","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0022","article-title":"Small-molecule-induced liquid-liquid phase separation suppresses the carcinogenesis of \u03b2-catenin","volume":"16","author":"Yan","year":"2025","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.clbc.2025.12.001_bib0023","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1111\/febs.16768","article-title":"MAEL facilitates metabolic reprogramming and breast cancer progression by promoting the degradation of citrate synthase and fumarate hydratase via chaperone-mediated autophagy","volume":"290","author":"Zhou","year":"2023","journal-title":"FEBS J"},{"key":"10.1016\/j.clbc.2025.12.001_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1083048","article-title":"The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness","volume":"14","author":"Andrade de Oliveira","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clbc.2025.12.001_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcdb.2016.08.025","article-title":"Molecular heterogeneity in breast cancer: state of the science and implications for patient care","volume":"64","author":"Ellsworth","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116615","article-title":"Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: advances and opportunities","volume":"175","author":"Yan","year":"2024","journal-title":"Biomed PharmacOther"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0027","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.06003","article-title":"Estrogen receptor \u03b2: an overview and update","volume":"6","author":"Zhao","year":"2008","journal-title":"Nucl Recept Signal"},{"key":"10.1016\/j.clbc.2025.12.001_bib0028","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2016.03.012","article-title":"Hormone receptor\/human epidermal growth factor receptor 2-positive breast cancer: Where we are now and where we are going","volume":"46","author":"Schettini","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2025.12.001_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0030","article-title":"Identification of transcription factors associated with the disease-free survival of triple-negative breast cancer through weighted gene co-expression network analysis","volume":"21","author":"Wang","year":"2024","journal-title":"Cytojournal"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0031","article-title":"Detection of transmembrane protein 100 in breast cancer: correlation with malignant progression and chemosensitivity","volume":"21","author":"Liu","year":"2024","journal-title":"Cytojournal"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0032","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s12282-017-0812-x","article-title":"Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K\/Akt\/mTOR in estrogen receptor-positive, HER2-negative breast cancer","volume":"25","author":"Araki","year":"2018","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0033","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes Dis"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0034","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/febs.16923","article-title":"The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond","volume":"291","author":"Saad","year":"2024","journal-title":"FEBS J"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0035","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semcdb.2008.11.002","article-title":"The \u201ca disintegrin and metalloprotease\u201d (ADAM) family of sheddases: physiological and cellular functions","volume":"20","author":"Reiss","year":"2009","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0036","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.bcp.2019.02.033","article-title":"Inhibition of MMPs and ADAM\/ADAMTS","volume":"165","author":"Malemud","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.clbc.2025.12.001_bib0037","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/HYPERTENSIONAHA.122.17963","article-title":"Disintegrin and metalloproteinases (ADAMs [a disintegrin and metalloproteinase] and ADAMTSs [ADAMs with a thrombospondin motif]) in aortic aneurysm","volume":"79","author":"Kilic","year":"2022","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188845","article-title":"Focus on mast cells in the tumor microenvironment: current knowledge and future directions","volume":"1878","author":"Shi","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.clbc.2025.12.001_bib0039","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bcp.2019.03.033","article-title":"A disintegrin and metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease","volume":"164","author":"Zhong","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-017-0599-6","article-title":"Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer","volume":"16","author":"Duhachek-Muggy","year":"2017","journal-title":"Mol Cancer"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e24805","article-title":"New insight into the role of the ADAM protease family in breast carcinoma progression","volume":"10","author":"Navasatli","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.clbc.2025.12.001_bib0042","unstructured":"Matthews J, Villescas S, Herat L, Schlaich M, Matthews V, Matthews VB. Implications of ADAM17 activation for hyperglycemia, obesity and type 2 diabetes. doi:10.1042\/BSR20210029\/908831\/bsr-2021-0029.pdf."},{"issue":"14","key":"10.1016\/j.clbc.2025.12.001_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21145133","article-title":"ADAM-mediated signalling pathways in gastrointestinal cancer formation","volume":"21","author":"Schumacher","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.clbc.2025.12.001_bib0044","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.bbamcr.2017.07.001","article-title":"The shedding protease ADAM17: physiology and pathophysiology","volume":"1864","author":"Zunke","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0045","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.bbamcr.2019.06.017","article-title":"Status update on iRhom and ADAM17: It\u2019s still complicated","volume":"1866","author":"D\u00fcsterh\u00f6ft","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0046","article-title":"A structural model of the iRhom\u2013ADAM17 sheddase complex reveals functional insights into its trafficking and activity","volume":"80","author":"Kahveci-T\u00fcrk\u00f6z","year":"2023","journal-title":"Cell Mole Life Sci"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0047","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.molcel.2023.12.012","article-title":"Cleavage of the pseudoprotease iRhom2 by the signal peptidase complex reveals an ER-to-nucleus signaling pathway","volume":"84","author":"Dulloo","year":"2024","journal-title":"Mol Cell"},{"issue":"401","key":"10.1016\/j.clbc.2025.12.001_bib0048","doi-asserted-by":"crossref","first-page":"ra109","DOI":"10.1126\/scisignal.aac5356","article-title":"Deletions in the cytoplasmic domain of iRhom1 and iRhom2 promote shedding of the TNF receptor by the protease ADAM17","volume":"8","author":"Maney","year":"2015","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0049","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03522-2","article-title":"Inflammatory activation of surface molecule shedding by upregulation of the pseudoprotease iRhom2 in colon epithelial cells","volume":"11","author":"Giese","year":"2021","journal-title":"Sci Rep"},{"issue":"18","key":"10.1016\/j.clbc.2025.12.001_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21186570","article-title":"Irhom2: an emerging adaptor regulating immunity and disease","volume":"21","author":"Al-Salihi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2025.12.001_bib0051","doi-asserted-by":"crossref","unstructured":"K\u00fc U, Grieve AG, Meng Y, Sieber B, Cowley SA, Freeman M. FRMD8 promotes inflammatory and growth factor signalling by stabilising the iRhom\/ADAM17 sheddase complex. 2018. doi:10.7554\/eLife.35012.001.","DOI":"10.7554\/eLife.35012.001"},{"issue":"17","key":"10.1016\/j.clbc.2025.12.001_bib0052","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259949","article-title":"iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells","volume":"135","author":"Sieber","year":"2022","journal-title":"J Cell Sci"},{"issue":"24","key":"10.1016\/j.clbc.2025.12.001_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.clbc.2025.12.001_bib0054","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28124672","article-title":"Small molecule inhibitors as therapeutic agents targeting oncogenic fusion proteins: current status and clinical","volume":"28","author":"Kong","year":"2023","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.001_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2021.119165","article-title":"Ectodomain shedding by ADAM proteases as a central regulator in kidney physiology and disease","volume":"1869","author":"Meyer-Schwesinger","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.clbc.2025.12.001_bib0056","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.canlet.2019.10.003","article-title":"ADAM proteases: emerging role and targeting of the non-catalytic domains","volume":"467","author":"Saha","year":"2019","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clbc.2025.12.001_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656908","article-title":"The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment","volume":"12","author":"Laha","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1108695","article-title":"Matrix metalloproteinases as therapeutic targets in breast cancer","volume":"12","author":"Kwon","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (Tnf-\u03b1) in autoimmune disease and current tnf-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clbc.2025.12.001_bib0060","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12262-021-02798-y","article-title":"Genetic predisposition to breast cancer and its management","volume":"83","author":"Srivastava","year":"2021","journal-title":"Indian J Surg"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0061","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0092-8674(88)90486-2","article-title":"A novel form of TNF\/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF","volume":"53","author":"Kriegler","year":"1988","journal-title":"TNF. Cell"},{"key":"10.1016\/j.clbc.2025.12.001_bib0062","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00584","article-title":"Tumor necrosis factor \u03b1 blockade: an opportunity to tackle breast cancer","volume":"10","author":"Mercogliano","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0063","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8739473","article-title":"Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage","volume":"2018","author":"Rayego-Mateos","year":"2018","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1016\/j.clbc.2025.12.001_bib0064","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091218","article-title":"ADAM17: an emerging therapeutic target for lung cancer","volume":"11","author":"Saad","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3892\/ijo.2016.3536","article-title":"ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation","volume":"49","author":"Meng","year":"2016","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0066","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10911-008-9084-6","article-title":"The ADAM17-amphiregulin-EGFR axis in mammary development and cancer","volume":"13","author":"Sternlicht","year":"2008","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0067","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3923\/ijp.2023.531.536","article-title":"Haplophyllum buxbaumii induces apoptosis via MAPK and AKT\/mTOR pathways in MCF-7 breast cancer cell line","volume":"19","author":"Kaplan","year":"2023","journal-title":"Int J Pharmacol"},{"issue":"11","key":"10.1016\/j.clbc.2025.12.001_bib0068","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4161\/cbt.8.11.8539","article-title":"ADAM17 promotes breast cancer cell malignant phenotype through EGFR\u2013PI3K\u2013AKT activation","volume":"8","author":"Zheng","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0069","article-title":"ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.clbc.2025.12.001_bib0070","article-title":"ADAM9 mediates triple-negative breast cancer progression via AKT\/NF-\u03baB Pathway","volume":"7","author":"Zhou","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0071","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-020-00396-1","article-title":"MTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci"},{"issue":"26","key":"10.1016\/j.clbc.2025.12.001_bib0072","doi-asserted-by":"crossref","first-page":"18393","DOI":"10.1074\/jbc.M801329200","article-title":"The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation","volume":"283","author":"Najy","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clbc.2025.12.001_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101041","article-title":"Furin, ADAM, and \u03b3-secretase: core regulatory targets in the notch pathway and the therapeutic potential for breast cancer","volume":"57","author":"Yao","year":"2024","journal-title":"Neoplasia"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0074","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021064","article-title":"Molecular targeting of the human epidermal growth factor receptor-2 (HER2) genes across various cancers","volume":"25","author":"Rubin","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0075","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1172\/JCI137552","article-title":"HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer","volume":"130","author":"de Heer","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clbc.2025.12.001_bib0076","article-title":"Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma","volume":"10","author":"Palumbo","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0077","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-020-01727-5","article-title":"ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc","volume":"21","author":"Cheng","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.clbc.2025.12.001_bib0078","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-physiol-021014-071720","article-title":"ADAM proteases and gastrointestinal function","volume":"78","author":"Jones","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0079","unstructured":"Wang R, Godet I, Yang Y, et al. Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis. doi:10.1073\/pnas.2020490118\/-\/DCSupplemental."},{"key":"10.1016\/j.clbc.2025.12.001_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1370800","article-title":"Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment","volume":"15","author":"Zhi","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2022.151220","article-title":"Multiple roles for basement membrane proteins in cancer progression and EMT","volume":"101","author":"Banerjee","year":"2022","journal-title":"Eur J Cell Biol"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0082","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1158\/0008-5472.CAN-13-1027","article-title":"Human rhomboid family-1 suppresses oxygen-independent degradation of hypoxia-inducible factor-1a in breast cancer","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"issue":"38","key":"10.1016\/j.clbc.2025.12.001_bib0083","doi-asserted-by":"crossref","first-page":"61273","DOI":"10.18632\/oncotarget.11341","article-title":"ADAMTS6 suppresses tumor progression via the ERK signaling pathway and serves as a prognostic marker in human breast cancer","volume":"7","author":"Xie","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2025.12.001_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1130823","article-title":"The versatile roles of ADAM8 in cancer cell migration, mechanics, and extracellular matrix remodeling","volume":"11","author":"Mierke","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.998475","article-title":"ERK signaling for cell migration and invasion","volume":"9","author":"Samson","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0086","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-015-0676-3","article-title":"The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family","volume":"16","author":"Kelwick","year":"2015","journal-title":"Genome Biol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0087","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.719993","article-title":"ADAMTS9-AS1 constrains breast cancer cell invasion and proliferation via sequestering miR-301b-3p","volume":"9","author":"Chen","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0088","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.654472","article-title":"The lncRNA ADAMTS9-AS2 regulates RPL22 to modulate TNBC progression via controlling the TGF-\u03b2 signaling pathway","volume":"11","author":"Ni","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0089","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-016-0699-z","article-title":"miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells","volume":"18","author":"Das","year":"2016","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2025.12.001_bib0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.866014","article-title":"IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment","volume":"12","author":"Manore","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2021.119141","article-title":"ADAM17 orchestrates interleukin-6, TNF\u03b1 and EGF-R signaling in inflammation and cancer","volume":"1869","author":"Schumacher","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0092","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0093","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.clbc.2025.12.001_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2023.119489","article-title":"EGFR stimulation enables IL-6 trans-signalling via iRhom2-dependent ADAM17 activation in mammary epithelial cells","volume":"1870","author":"Schumacher","year":"2023","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0095","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/cas.13985","article-title":"A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients","volume":"110","author":"Zmetakova","year":"2019","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0096","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13058-020-01298-3","article-title":"FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors","volume":"22","author":"Paul","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0097","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/s12885-018-4783-x","article-title":"Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers","volume":"18","author":"Kalinkova","year":"2018","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0098","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/onc.2014.70","article-title":"Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals","volume":"34","author":"Costa","year":"2015","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0099","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/1078-0432.CCR-08-1585","article-title":"Role of ADAMs in cancer formation and progression","volume":"15","author":"Duffy","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0100","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/cancers4041252","article-title":"Emerging Roles of ADAMTSs in angiogenesis and cancer","volume":"4","author":"Kumar","year":"2012","journal-title":"Cancers (Basel)"},{"issue":"6_Supplement","key":"10.1016\/j.clbc.2025.12.001_bib0101","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1158\/1538-7445.AM2024-2893","article-title":"Abstract 2893: inhibition of ADAMTS4 and 5 to regulate the tumor microenvironment","volume":"84","author":"Lee","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2025.12.001_bib0102","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.2147\/OTT.S248085","article-title":"Adamts8 inhibits cell proliferation and invasion, and induces apoptosis in breast cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0103","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-4598-12-2","article-title":"Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion","volume":"12","author":"Freitas","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clbc.2025.12.001_bib0104","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.matbio.2015.01.013","article-title":"ADAMTS proteases and cancer","volume":"44-46","author":"Cal","year":"2015","journal-title":"Matrix Biol"},{"issue":"9","key":"10.1016\/j.clbc.2025.12.001_bib0105","doi-asserted-by":"crossref","first-page":"10243","DOI":"10.18632\/oncotarget.7200","article-title":"ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3","volume":"7","author":"Ebbing","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.001_bib0106","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10549-012-2220-4","article-title":"An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer","volume":"135","author":"Li","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0107","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3844\/ajisp.2012.123.135","article-title":"The cell to cell interaction of breast cancer cells regulates cancer invasion via ADAM15","volume":"8","author":"Ota","year":"2012","journal-title":"Am J Immunol"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0108","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/10409231003628015","article-title":"ADAM-17: the enzyme that does it all","volume":"45","author":"Gooz","year":"2010","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0109","article-title":"Immunomodulatory role of metalloproteinase ADAM17 in tumor development","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clbc.2025.12.001_bib0110","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.28295","article-title":"TACE-dependent TGF\u03b1 shedding drives triple-negative breast cancer cell invasion","author":"Giricz","year":"2013","journal-title":"Int J Cancer"},{"issue":"20","key":"10.1016\/j.clbc.2025.12.001_bib0111","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2174\/138161209788682424","article-title":"ADAM28 as a target for human cancers","volume":"15","author":"Mochizuki","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clbc.2025.12.001_bib0112","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1148162","article-title":"The role of ADAM8 in the mechanophenotype of MDA-MB-231 breast cancer cells in 3D extracellular matrices","volume":"11","author":"Hayn","year":"2023","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0113","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/cas.13985","article-title":"A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients","volume":"110","author":"Zmetakova","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clbc.2025.12.001_bib0114","unstructured":"Zhao M., Jia W., Cheng S., Song M., et al. ADAM29 expression in human breast cancer and its effects on breast cancer cells in vitro. Anticancer Research. 2016;36(3):1251\u20131258."},{"key":"10.1016\/j.clbc.2025.12.001_bib0115","doi-asserted-by":"crossref","DOI":"10.1038\/srep44414","article-title":"Down regulation of ADAM33 as a predictive biomarker of aggressive breast cancer","volume":"7","author":"Manica","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0116","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3892\/ijo.2015.3015","article-title":"miR-365 overexpression promotes cell proliferation and invasion by targeting ADAMTS-1 in breast cancer","volume":"47","author":"LI","year":"2015","journal-title":"Int J Oncol"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0117","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/ijc.28271","article-title":"Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2","volume":"133","author":"Martino-Echarri","year":"2013","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.001_bib0118","first-page":"1553","article-title":"ADAMTS1 promotes adhesion to extracellular matrix proteins and predicts prognosis in early stage breast cancer patients","volume":"52","author":"Tan","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.clbc.2025.12.001_bib0119","doi-asserted-by":"crossref","unstructured":"Fontanil T., \u00c1lvarez-Teijeiro S., \u00c1ngeles Villaronga M., et al. Cleavage of fibulin-2 by the Aggrecanases ADAMTS-4 and ADAMTS-5 contributes to the tumorigenic potential of breast cancer cells. Oncotarget. 2017;8(8):13716\u201313729. doi:10.18632\/oncotarget.14627.","DOI":"10.18632\/oncotarget.14627"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0120","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/jcmm.13404","article-title":"The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer","volume":"22","author":"Shao","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042288","article-title":"New and emerging targeted therapies for advanced breast cancer","volume":"23","author":"Lau","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.001_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188991","article-title":"Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis","volume":"1878","author":"P\u00fcsk\u00fcll\u00fco\u011flu","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0123","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7150\/thno.21674","article-title":"Current challenges of cancer anti-angiogenic therapy and the promise of nanotherapeutics","volume":"8","author":"Abdalla","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.001_bib0124","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030563","article-title":"Recent progress of stem cell therapy in cancer treatment: Molecular mechanisms and potential applications","volume":"9","author":"Chu","year":"2020","journal-title":"Cells"},{"issue":"15","key":"10.1016\/j.clbc.2025.12.001_bib0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241511903","article-title":"Antibody-drug conjugates for breast cancer treatment: emerging agents, targets and future directions","volume":"24","author":"Yang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.clbc.2025.12.001_bib0126","doi-asserted-by":"crossref","DOI":"10.3390\/biom13081207","article-title":"Challenges and opportunities in developing targeted therapies for triple negative breast cancer","volume":"13","author":"Chapdelaine","year":"2023","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0127","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.clbc.2025.03.006","article-title":"Harnessing artificial intelligence for precision diagnosis and treatment of triple negative breast cancer","volume":"25","author":"Hussain","year":"2025","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.001_bib0128","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1109\/TCBB.2020.2973148","article-title":"FUNMarker: fusion network-based method to identify prognostic and heterogeneous breast cancer Biomarkers","volume":"18","author":"Li","year":"2021","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"key":"10.1016\/j.clbc.2025.12.001_bib0129","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.119126","article-title":"Chrysotoxine regulates ferroptosis and the PI3K\/AKT\/mTOR pathway to prevent cervical cancer","volume":"338","author":"Zhou","year":"2025","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101323","article-title":"Post-translational regulation and proteolytic activity of the metalloproteinase ADAMTS8","volume":"297","author":"Santamaria","year":"2021","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.clbc.2025.12.001_bib0131","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cac2.70048","article-title":"Short-chain acyl post-translational modifications in cancers: mechanisms, roles, and therapeutic implications","volume":"45","author":"Wu","year":"2025","journal-title":"Cancer Commun"},{"key":"10.1016\/j.clbc.2025.12.001_bib0132","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00499","article-title":"Targeting ADAM10 in cancer and autoimmunity","volume":"11","author":"Smith","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0133","doi-asserted-by":"crossref","DOI":"10.3390\/biom8040163","article-title":"Triptolide decreases cell proliferation and induces cell death in triple negative MDA-MB-231 breast cancer cells","volume":"8","author":"Varghese","year":"2018","journal-title":"Biomolecules"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.001_bib0134","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/1078-0432.CCR-06-2116","article-title":"Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer","volume":"13","author":"Fridman","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.clbc.2025.12.001_bib0135","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1158\/0008-5472.CAN-08-0739","article-title":"Synergistic inhibition with a dual epidermal growth factor receptor\/HER-2\/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor","volume":"68","author":"Witters","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2025.12.001_bib0136","article-title":"Extracellular Matrix: emerging roles and potential therapeutic targets for breast cancer","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0137","article-title":"Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics","volume":"40","author":"Cuciniello","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0138","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10555-017-9717-6","article-title":"RNA interference-based therapy and its delivery systems","volume":"37","author":"Chen","year":"2018","journal-title":"Cancer Metastasis Rev"},{"issue":"12","key":"10.1016\/j.clbc.2025.12.001_bib0139","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1021\/acscombsci.0c00099","article-title":"Progress in natural compounds\/siRNA Co-delivery employing nanovehicles for cancer therapy","volume":"22","author":"Ashrafizadeh","year":"2020","journal-title":"ACS Comb Sci"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0140","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s12094-022-03043-y","article-title":"siRNA and targeted delivery systems in breast cancer therapy","volume":"25","author":"Mirzaei","year":"2023","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0141","first-page":"1640","article-title":"Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF-7 cells in vitro and in vivo and its mechanism of action","volume":"39","author":"Hu","year":"2018","journal-title":"Oncol Rep"},{"issue":"7","key":"10.1016\/j.clbc.2025.12.001_bib0142","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.biochi.2013.03.001","article-title":"ADAM9 silencing inhibits breast tumor cell invasion in vitro","volume":"95","author":"Micocci","year":"2013","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.clbc.2025.12.001_bib0143","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2021.10452","article-title":"MicroRNA449a inhibits cell proliferation and migration by regulating mutant p53 in MDAMB468 cells","volume":"22","author":"Huang","year":"2021","journal-title":"Exp Ther Med"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0144","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000493964","article-title":"MiR-449a suppresses tamoxifen resistance in human breast cancer cells by targeting ADAM22","volume":"50","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"182","key":"10.1016\/j.clbc.2025.12.001_bib0145","doi-asserted-by":"crossref","first-page":"559","DOI":"10.24976\/Discov.Med.202436182.52","article-title":"DNA Methylation-Regulated HOXC8\u2019s role in HER2-positive breast cancer function and its contribution to Herceptin resistance","volume":"36","author":"Xie","year":"2024","journal-title":"Discov Med"},{"issue":"4","key":"10.1016\/j.clbc.2025.12.001_bib0146","doi-asserted-by":"crossref","DOI":"10.3390\/polym11040745","article-title":"Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications","volume":"11","author":"Rai","year":"2019","journal-title":"Polymers (Basel)"},{"issue":"16","key":"10.1016\/j.clbc.2025.12.001_bib0147","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25163731","article-title":"Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology","volume":"25","author":"Zielinska","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.clbc.2025.12.001_bib0148","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6541132","article-title":"Calcium phosphorus nanoparticles coloaded with paclitaxel and adam-10-sirna for the treatment of triple negative breast cancer","volume":"2022","author":"He","year":"2022","journal-title":"J Nanomater"},{"key":"10.1016\/j.clbc.2025.12.001_bib0149","doi-asserted-by":"crossref","DOI":"10.1007\/s40005-025-00731-z","article-title":"Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy","author":"Yuan","year":"2025","journal-title":"J Pharm Investig"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0150","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1039\/C8AN02344A","article-title":"Rapid and sensitive detection of the activity of ADAM17 using a graphene oxide-based fluorescence sensor","volume":"144","author":"Zhang","year":"2019","journal-title":"Analyst"},{"issue":"5","key":"10.1016\/j.clbc.2025.12.001_bib0151","doi-asserted-by":"crossref","DOI":"10.3788\/COL202018.051701","article-title":"Detection of breast cancer based on novel porous silicon Bragg reflector surface-enhanced Raman spectroscopy-active structure","volume":"18","author":"Ma","year":"2020","journal-title":"Chin Opt Lett"},{"key":"10.1016\/j.clbc.2025.12.001_bib0152","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2022.122000","article-title":"Serum Raman spectroscopy combined with convolutional neural network for rapid diagnosis of HER2-positive and triple-negative breast cancer","volume":"286","author":"Zeng","year":"2023","journal-title":"Spectrochim Acta a Mol Biomol Spectrosc"},{"issue":"2","key":"10.1016\/j.clbc.2025.12.001_bib0153","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1172\/JCI29518","article-title":"Targeting TACE-dependent EGFR ligand shedding in breast cancer","volume":"117","author":"Kenny","year":"2007","journal-title":"J Clinical Invest"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0154","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-016-0013-4","article-title":"Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate","volume":"6","author":"Madoux","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.001_bib0155","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/bjc.2015.288","article-title":"ADAM10: a new player in breast cancer progression?","volume":"113","author":"Mullooly","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2025.12.001_bib0156","article-title":"A disintegrin and metalloproteinase domain 10 expression inhibition by the small molecules adenosine, cordycepin and N6, N6-dimethyladenosine and immune regulation in malignant cancers","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.clbc.2025.12.001_bib0157","doi-asserted-by":"crossref","first-page":"10963","DOI":"10.18632\/oncotarget.2794","article-title":"ADAM10 and ADAM17: new players in trastuzumab resistance","volume":"5","author":"Duffy","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.clbc.2025.12.001_bib0158","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9673537","article-title":"Recent advances in ADAM17 research: a promising target for cancer and inflammation","volume":"2017","author":"Moss","year":"2017","journal-title":"Mediators Inflamm"},{"issue":"6","key":"10.1016\/j.clbc.2025.12.001_bib0159","doi-asserted-by":"crossref","first-page":"648","DOI":"10.4161\/cbt.5.6.2707","article-title":"Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab","volume":"5","author":"Liu","year":"2006","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0160","doi-asserted-by":"crossref","DOI":"10.1186\/s11658-025-00754-2","article-title":"FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-\u03b1","volume":"30","author":"Xu","year":"2025","journal-title":"Cell Mol Biol Lett"},{"issue":"21","key":"10.1016\/j.clbc.2025.12.001_bib0161","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.4161\/cbt.8.21.9803","article-title":"Triptolide: an inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells","volume":"8","author":"Soundararajan","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"10.1016\/j.clbc.2025.12.001_bib0162","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101265","article-title":"Inhibitory monoclonal antibody targeting ADAM17 expressed on cancer cells","volume":"15","author":"Saha","year":"2022","journal-title":"Transl Oncol"},{"issue":"12","key":"10.1016\/j.clbc.2025.12.001_bib0163","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/bjc.2015.163","article-title":"Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells","volume":"112","author":"Caiazza","year":"2015","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.clbc.2025.12.001_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102225","article-title":"Metalloprotease ADAM9 cleaves ephrin-B ligands and differentially regulates Wnt and mTOR signaling downstream of Akt kinase in colorectal cancer cells","volume":"298","author":"Chandrasekera","year":"2022","journal-title":"Journal of Biological Chemistry"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925003477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820925003477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:47:43Z","timestamp":1779450463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820925003477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":164,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1526820925003477"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2025.12.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ADAM and ADAMTS Proteases in Breast Cancer: Molecular Mechanisms and Therapeutic Implications","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2025.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}